First SITC Guidelines in RCC Address Continuing Role of Interleukin-2 and Emergence of NivolumabFebruary 21st 2017
New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.
Genitourinary Cancer Field Gets Off to an Eventful Start in 2017February 15th 2017
The field of genitourinary (GU) cancers is starting to undergo some of the same changes that have been shifting treatment paradigms so dramatically in other malignancies. The most significant change can be summed up in one word: immunotherapy.